by A groundbreaking, randomized clinical trial, spearheaded by a partnership between Duke-NUS Medical School, National Heart Center Singapore (NHCS), and Klinikum Nürnberg, Germany, has unveiled unexpected insights into the cardiac advantages of SGLT2 inhibitor drugs, initially designed for diabetes management.
Contrary to popular belief, these medications may enhance heart health and cardiac outcomes without exerting diuretic properties.
Heart failure refers to a condition where the heart struggles to pump sufficient blood to meet the body’s requirements, leading to tissue congestion and blood circulation issues. This congestion puts extra pressure on the Beating Heart, causing symptoms such as shortness of breath and swelling.
To effectively manage heart failure, it’s crucial to alleviate congestion, as this lessens the heart’s workload and facilitates pumping.
SGLT2 inhibitor drugs have emerged as the latest breakthrough treatment for chronic heart failure due to their rapid ability to stabilize heart function and decrease hospitalizations and mortality rates. These drugs promote the excretion of additional glucose into the urine, potentially drawing more fluid from the body into the urine, thereby relieving the fluid build-up and congestion experienced by heart disease patients.
Despite their diuretic potential, drug information sheets caution patients about the risk of dehydration as a common side effect.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
